4CPS-181 HIV pre-exposure prophylaxis in real-world setting: tolerance and adherence

<h3>Background and Importance</h3> Pre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy for people at high-risk of infection. Long-term studies of adherence and tolerance to PrEP are limited. <h3>Aim and Objectives</h3> To evaluate the tolerance and adherence of HIV PrEP in a real-world setting. <h3>Material and Methods</h3> A cross-sectional observational study was designed in a third-level hospital. Daily dose PrEP users with a minimum follow-up of 3 months were included. Users were followed from June 2024 to August 2024. On-demand PrEP users were excluded. Socio-demographic data, sexually transmitted diseases (STDs) diagnosis and treatment variables were collected. Tolerance data were collected from the electronic medical record. Adherence was analysed using the Simplified Medication Adherence Questionnaire (SMAQ) (users were considered adherent when the SMAQ percentage was 100%), and the medication possession ratio (MPR) (users were considered adherent when the MPR was ≥ 0.8). <h3>Results</h3> <h3>Conclusion and Relevance</h3> Less than 20% of users experienced an adverse effect. The most frequent were hypophosphataemia and diarrhoea. Although renal failure was less frequent, it required in one case a switch from TDF to tenofovir alafenamide (TAF) due to its lower renal toxicity. About adherence, the MPR showed higher adherence compared to the SMAQ questionnaire. This could be explained, on the one hand, by the restrictive nature of the SMAQ questionnaire and, on the other hand, because users may have had more medication than they declared in the interview, according to the dispensing data. In this sense, more studies related to non-adherence and its causes are needed. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest